Leptomeningeal Metastases in Non-small Cell Lung Cancer: Optimal Systemic Management in NSCLC With and Without Driver Mutations

Palliative cerebrospinal fluid shunting for leptomeningeal metastasis-related hydrocephalus in patients with lung adenocarcinoma: A single-center retrospective study

(2019) Koichi Mitsuya et al.   PLoS One

Outcome and prognostic factors following palliative craniospinal irradiation for leptomeningeal carcinomatosis

(2019) Rami A. El Shafie et al.   Cancer Management and Research

Clinical outcome of cerebrospinal fluid shunts in patients with leptomeningeal carcinomatosis

(2019) Hye Seon Kim et al.   World Journal of Surgical Oncology

The RANO Leptomeningeal Metastasis Group proposal to assess response to treatment: lack of feasibility and clinical utility and a revised proposal

(2019) Emilie Le Rhun et al.   NEURO-ONCOLOGY

Outcome of Patients with Non–Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint Inhibitors

(2019) Lizza E.L. Hendriks et al.   Journal of Thoracic Oncology

Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-positive Advanced Non-small-cell Lung Cancer in the Global Phase III ALEX Study

(2019) D. Ross Camidge et al.   Journal of Thoracic Oncology

Pemetrexed in the treatment of leptomeningeal metastasis in patients with EGFR-mutant lung cancer

(2019) Mihong Choi et al.   Clinical Lung Cancer

105OOsimertinib for patients (pts) with leptomeningeal metastases (LM) associated with EGFRm advanced NSCLC: The AURA LM study

(2019) M-J Ahn et al.   ANNALS OF ONCOLOGY

Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001

(2019) A T Shaw et al.   ANNALS OF ONCOLOGY

Efficacy of entrectinib in patients (pts) with solid tumors and central nervous system (CNS) metastases: Integrated analysis from three clinical trials.

(2019) Salvatore Siena et al.   JOURNAL OF CLINICAL ONCOLOGY

Afatinib helped overcome subsequent resistance to osimertinib in a patient with NSCLC having leptomeningeal metastasis baring acquired EGFR L718Q mutation: a case report

(2019) Jing Liu et al.   BMC CANCER

Survival of patients with non-small cell lung cancer having leptomeningeal metastases treated with immune checkpoint inhibitors

(2019) Lizza E.L. Hendriks et al.   EUROPEAN JOURNAL OF CANCER

Intra-cranial efficacy of brigatinib in an ALK-positive non-small cell lung cancer patient presenting leptomeningeal carcinomatosis

(2019) Elisabeth Gaye et al.   LUNG CANCER

Four-Year Lasting Sustained Complete Response After Nivolumab in a Patient With Non–Small-Cell Lung Cancer and Confirmed Leptomeningeal Carcinomatosis: Changing the Paradigm

(2019) Mateo Bover et al.   Clinical Lung Cancer

Whole brain radiation therapy does not improve the overall survival of EGFR-mutant NSCLC patients with leptomeningeal metastasis

(2019) Weiwei Yan et al.   Radiation Oncology

A Pilot Phase 1 Study of Intrathecal Pemetrexed for Refractory Leptomeningeal Metastases From Non-small-cell Lung Cancer

(2019) Zhenyu Pan et al.   Frontiers in Oncology

Dramatic Response of Leptomeningeal Carcinomatosis to Nivolumab in PD-L1 Highly Expressive Non-small Cell Lung Cancer: A Case Report

(2019) David Arias Ron et al.   Frontiers in Oncology

OA07.01 Osimertinib Plus Platinum/Pemetrexed in Newly-Diagnosed Advanced EGFRm-Positive NSCLC; The Phase 3 FLAURA2 Study

(2019) P. Jänne et al.   Journal of Thoracic Oncology

Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC

(2019) Suresh S. Ramalingam et al.   NEW ENGLAND JOURNAL OF MEDICINE

Radiotherapy in Leptomeningeal Disease: A Systematic Review of Randomized and Non-randomized Trials

(2019) Samantha M. Buszek et al.   Frontiers in Oncology

Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation–Positive Non–Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study

(2019) James C.H. Yang et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical and Radiographic Response of Leptomeningeal and Brain Metastases to Encorafenib and Binimetinib in a Patient With BRAF V600E-Mutated Lung Adenocarcinoma

(2019) Erin M. McLoughlin et al.   Journal of Thoracic Oncology

Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1–2 trial

(2019) Alice T Shaw et al.   LANCET ONCOLOGY

Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials

(2019) Robert C Doebele et al.   LANCET ONCOLOGY

Selective RET kinase inhibition for patients with RET-altered cancers

(2018) V Subbiah et al.   ANNALS OF ONCOLOGY

Unique genetic profiles from cerebrospinal fluid cell-free DNA in leptomeningeal metastases of EGFR-mutant non-small-cell lung cancer: a new medium of liquid biopsy

(2018) Y S Li et al.   ANNALS OF ONCOLOGY

Long leptomeningeal responses with brigatinib in two heavily pre-treated ALK-rearranged non-small cell lung cancer patients

(2018) Arthur Geraud et al.   Journal of Thoracic Oncology

Leptomeningeal metastases in non-small-cell lung cancer

(2018) Haiying Cheng et al.   LANCET ONCOLOGY

Great efficacy of bevacizumab plus erlotinib for leptomeningeal metastases from non-small cell lung cancer with initially positive EGFR mutation: a case report

(2018) Wang Jing et al.   CANCER BIOLOGY & THERAPY

Outcomes of lung cancer patients with leptomeningeal metastases in the targeted therapy era.

(2018) Kathryn Sara Nevel et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II study of pembrolizumab in leptomeningeal carcinomatosis.

(2018) Priscilla Kaliopi Brastianos et al.   JOURNAL OF CLINICAL ONCOLOGY

CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer

(2018) Thanyanan Reungwetwattana et al.   JOURNAL OF CLINICAL ONCOLOGY

Non-small cell lung cancer leptomeningeal metastases treated with intrathecal therapy plus osimertinib and temozolomide and whole-brain radiation therapy: a case report

(2018) yunmei Wang et al.   OncoTargets and Therapy

OA08.07 BRAF-V600E Advanced Lung Adenocarcinoma with Leptomeningeal (LM) Disease Treated with Vemurafenib

(2017) Maria Gabriela Fernandes et al.   Journal of Thoracic Oncology

Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study

(2017) Myung-Ju Ahn et al.   Lancet Respiratory Medicine

Leptomeningeal metastases of solid cancer

(2016) Emilie Le Rhun et al.   CURRENT OPINION IN NEUROLOGY

Leptomeningeal metastasis: Clinical experience of 519 cases

(2016) Jae-Won Hyun et al.   EUROPEAN JOURNAL OF CANCER

Leptomeningeal Metastases in Patients with NSCLC with EGFR Mutations

(2016) Yang-Si Li et al.   Journal of Thoracic Oncology

Alectinib Dose Escalation Reinduces Central Nervous System Responses in Patients with Anaplastic Lymphoma Kinase–Positive Non–Small Cell Lung Cancer Relapsing on Standard Dose Alectinib

(2016) Justin F. Gainor et al.   Journal of Thoracic Oncology

Intrathecal chemotherapy as a treatment for leptomeningeal metastasis of non-small cell lung cancer: A pooled analysis

(2016) Ya-Lan Wu et al.   Oncology Letters

High-dose erlotinib for refractory leptomeningeal metastases after failure of standard-dose EGFR-TKIs

(2015) Takahisa Kawamura et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non–Small-Cell Lung Cancer Patients with Leptomeningeal Carcinomatosis

(2015) Bin-Chi Liao et al.   Journal of Thoracic Oncology

CellSearch® technology applied to the detection and quantification of tumor cells in CSF of patients with lung cancer leptomeningeal metastasis

(2015) Qian Tu et al.   LUNG CANCER

Brain metastases in patients with EGFR -mutated or ALK -rearranged non-small-cell lung cancers

(2015) Deepa Rangachari et al.   LUNG CANCER

Treatment and survival of patients with EGFR -mutated non-small cell lung cancer and leptomeningeal metastasis: A retrospective cohort analysis

(2015) Justine L. Kuiper et al.   LUNG CANCER

Novel method for the detection and quantification of malignant cells in the CSF of patients with leptomeningeal metastasis of lung cancer

(2015) CHUNHUA MA et al.   Oncology Letters

Prolonged Survival of Patients With Non–Small-Cell Lung Cancer With Leptomeningeal Carcinomatosis in the Modern Treatment Era

(2014) Jonathan W. Riess et al.   Clinical Lung Cancer

Leptomeningeal Carcinomatosis in Non–Small-Cell Lung Cancer Patients: Impact on Survival and Correlated Prognostic Factors

(2013) Su Jin Lee et al.   Journal of Thoracic Oncology

Erlotinib Versus Gefitinib for Control of Leptomeningeal Carcinomatosis in Non–Small-Cell Lung Cancer

(2013) Eunyoung Lee et al.   Journal of Thoracic Oncology

The Central Nervous System as a Sanctuary Site in ALK-Positive Non–Small-Cell Lung Cancer

(2013) Justin F. Gainor et al.   Journal of Thoracic Oncology

Rare cell capture technology for the diagnosis of leptomeningeal metastasis in solid tumors

(2013) L. Nayak et al.   NEUROLOGY

Clinical outcome in patients with leptomeningeal metastasis from non-small cell lung cancer: Okayama Lung Cancer Study Group

(2012) Shigeki Umemura et al.   LUNG CANCER

"Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer

(2011) C. Grommes et al.   NEURO-ONCOLOGY

Restricted brain penetration of the tyrosine kinase inhibitor erlotinib due to the drug transporters P-gp and BCRP

(2010) Nienke A. de Vries et al.   INVESTIGATIONAL NEW DRUGS

Identification of Leptomeningeal Disease in Aggressive B-Cell Non-Hodgkin's Lymphoma: Improved Sensitivity of Flow Cytometry

(2009) Sandra Quijano et al.   JOURNAL OF CLINICAL ONCOLOGY

Diagnostic Tools for Neoplastic Meningitis: Detecting Disease, Identifying Patient Risk, and Determining Benefit of Treatment

(2009) Marc C. Chamberlain et al.   SEMINARS IN ONCOLOGY